Chromogranin A as a determinant of midgut carcinoid tumour volume

Regulatory Peptides

Volumn 120, Issue 1-3, 2004, Pages 269-273

  Kölby, Lars ^a   Bernhardt, Peter ^a   Swärd, Christina ^a   Johanson, Viktor ^a   Ahlman, Håkan ^a   Forssell Aronsson, Eva ^a   Stridsberg, Mats ^b   Wängberg, Bo ^a   Nilsson, Ola ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Carcinoid tumours; Chromogranin A; Neuroendocrine; Octreotide

Indexed keywords

CHROMOGRANIN A; OCTREOTIDE; SOMATOSTATIN DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOID; CONTROLLED STUDY; CORRELATION ANALYSIS; ILEUM CANCER; MALE; MIDGUT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STATISTICAL SIGNIFICANCE; TUMOR VOLUME; XENOGRAFT;

ANIMALS; CARCINOID TUMOR; CHROMOGRANIN A; CHROMOGRANINS; GASTROINTESTINAL AGENTS; HUMANS; ILEAL NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; OCTREOTIDE; TRANSPLANTATION, HETEROLOGOUS; TREATMENT OUTCOME; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

ANIMALIA; MUS MUSCULUS;

EID: 2642580649     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2004.03.017     Document Type: Article

References (34)

1. Smith A.D., Winkler H. Purification and properties of an acidic protein from chromaffin granules of bovine adrenal medulla. Biochem. J. 103(2):1967;483-492
2. Banks P., Helle K. The release of protein from the stimulated adrenal medulla. Biochem. J. 97(3):1965;40C-41C
3. Blaschko H., Comline R.S., Schneider F.H., Silver M., Smith A.D. Secretion of a chromaffin granule protein, chromogranin, from the adrenal gland after splanchnic stimulation. Nature. 215(96):1967;58-59
4. Smith W.J., Kirshner N. A specific soluble protein from the catecholamine storage vesicles of bovine adrenal medulla: I. Purification and chemical characterization. Mol. Pharmacol. 3(1):1967;52-62
5. Deftos L.J. Chromogranin A: its role in endocrine function and as an endocrine and neuroendocrine tumor marker. Endocr. Rev. 12(2):1991;181-187
6. Hendy G.N., Bevan S., Mattei M.G., Mouland A.J. Chromogranin A. Clin. Invest. Med. 18(1):1995;47-65
7. Winkler H., Fischer-Colbrie R. The chromogranins A and B: the first 25 years and future perspectives. Neuroscience. 49(3):1992;497-528
8. 2+-dependent endopeptidase and carboxypeptidase H (EC 3.4.17.10). Biochem. J. 244(2):1987;457-464
9. Tatemoto K., Efendic S., Mutt V., Makk G., Feistner G.J., Barchas J.D. Pancreastatin, a novel pancreatic peptide that inhibits insulin secretion. Nature. 324(6096):1986;476-478
10. Bajetta E., Ferrari L., Martinetti A., Celio L., Procopio G., Artale S., et al. Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer. 86(5):1999;858-865
11. Pirker R.A., Pont J., Pöhnl R., Schütz W., Griesmacher A., Müller M.M. Usefulness of chromogranin A as a marker for detection of relapses of carcinoid tumours. Clin. Chem. Lab. Med. 36(11):1998;837-840
12. Baudin E., Gigliotti A., Ducreux M., Ropers J., Comoy E., Sabourin J.C., et al. Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours. Br. J. Cancer. 78(8):1998;1102-1107
13. Hsiao R.J., Neumann H.P., Parmer R.J., Barbosa J.A., O'Connor D.T. Chromogranin A in familial pheochromocytoma: diagnostic screening value, prediction of tumor mass, and post-resection kinetics indicating two-compartment distribution. Am. J. Med. 88(6):1990;607-613
14. Moattari A.R., Deftos L.J., Vinik A.I. Effects of sandostatin on plasma chromogranin-A levels in neuroendocrine tumors. J. Clin. Endocrinol. Metab. 69(4):1989;902-905
15. Westberg G. Midgut Carcinoid Tumours, Biochemical and Therapeutic Aspects. 2001;University of Göteborg, Göteborg
16. Kölby L., Bernhardt P., Ahlman H., Wängberg B., Johanson V., Wigander A., et al. A transplantable human carcinoid as model for somatostatin receptor-mediated and amine transporter-mediated radionuclide uptake. Am. J. Pathol. 158(2):2001;745-755
17. Stridsberg M., Hellman U., Wilander E., Lundqvist G., Hellsing K., Öberg K. Fragments of chromogranin A are present in the urine of patients with carcinoid tumours: development of a specific radioimmunoassay for chromogranin A and its fragments. J. Endocrinol. 139(2):1993;329-337
18. Stridsberg M., Öberg K., Li Q., Engström U., Lundqvist G. Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. J. Endocrinol. 144(1):1995;49-59
19. R.O. Kuehl, Statistical Principles of Research Design and Analysis. Belmont, CA: Duxbury Press; 1994. p. 93-5, 562-4.
20. Nobels F.R., de Herder W.W., Kwekkeboom D.J., Coopmans W., Mulder A., Bouillon R., et al. Serum chromogranin A in the differential diagnosis of Cushing's syndrome. Eur. J. Endocrinol. 131(6):1994;589-593
21. Nobels F.R., Kwekkeboom D.J., Bouillon R., Lamberts S.W. Chromogranin A: its clinical value as marker of neuroendocrine tumours. Eur. J. Clin. Investig. 28(6):1998;431-440
22. Borch K., Stridsberg M., Burman P., Rehfeld J.F. Basal chromogranin A and gastrin concentrations in circulation correlate to endocrine cell proliferation in type-A gastritis. Scand. J. Gastroenterol. 32(3):1997;198-202
23. Cubeddu L.X., O'Connor D.T., Hoffmann I., Parmer R.J. Plasma chromogranin A marks emesis and serotonin release associated with dacarbazine and nitrogen mustard but not with cyclophosphamide- based chemotherapies. Br. J. Cancer. 72(4):1995;1033-1038
24. Hsiao R.J., Mezger M.S., O'Connor D.T. Chromogranin A in uremia: progressive retention of immunoreactive fragments. Kidney Int. 37(3):1990;955-964
25. Sanduleanu S., Stridsberg M., Jonkers D., Hameeteman W., Biemond I., Lundqvist G., et al. Serum gastrin and chromogranin A during medium- and long-term acid suppressive therapy: a case - control study. Aliment. Pharmacol. Ther. 13(2):1999;145-153
26. Giovanella L., La Rosa S., Ceriani L., Uccella S., Erba P., Garancini S. Chromogranin-A as a serum marker for neuroendocrine tumors: comparison with neuron-specific enolase and correlation with immunohistochemical findings. Int. J. Biol. Markers. 14(3):1999;160-166
27. Wassberg E., Stridsberg M., Christofferson R. Plasma levels of chromogranin A are directly proportional to tumour burden in neuroblastoma. J. Endocrinol. 151(2):1996;225-230
28. Bousquet C., Puente E., Buscail L., Vaysse N., Susini C. Antiproliferative effect of somatostatin and analogs. Chemotherapy. 47(Suppl. 2):2001;30-39
29. Saltz L., Trochanowski B., Buckley M., Heffernan B., Niedzwiecki D., Tao Y., et al. Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer. 72(1):1993;244-248
30. Arnold R., Trautmann M.E., Creutzfeldt W., Benning R., Benning M., Neuhaus C., et al. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut. 38(3):1996;430-438
31. Gorden P., Comi R.J., Maton P.N., Go V.L. NIH conference. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut. Ann. Intern. Med. 110(1):1989;35-50
32. Kvols L.K., Moertel C.G., O'Connell M.J., Schutt A.J., Rubin J., Hahn R.G. Treatment of the malignant carcinoid syndrome. Evaluation of a long- acting somatostatin analogue. N. Engl. J. Med. 315(11):1986;663-666
33. Westberg G., Ahlman H., Nilsson O., Illerskog A., Wängberg B. Secretory patterns of tryptophan metabolites in midgut carcinoid tumor cells. Neurochem. Res. 22(8):1997;977-983
34. Wängberg B., Nilsson O., Theodorsson E., Dahlström A., Ahlman H. The effect of a somatostatin analogue on the release of hormones from human midgut carcinoid tumour cells. Br. J. Cancer. 64(1):1991;23-28